1. Home
  2. GBIO vs VATE Comparison

GBIO vs VATE Comparison

Compare GBIO & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • VATE
  • Stock Information
  • Founded
  • GBIO 2016
  • VATE 1994
  • Country
  • GBIO United States
  • VATE United States
  • Employees
  • GBIO N/A
  • VATE N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • VATE Metal Fabrications
  • Sector
  • GBIO Health Care
  • VATE Industrials
  • Exchange
  • GBIO Nasdaq
  • VATE Nasdaq
  • Market Cap
  • GBIO 64.8M
  • VATE 63.4M
  • IPO Year
  • GBIO 2020
  • VATE 1996
  • Fundamental
  • Price
  • GBIO $0.78
  • VATE $11.86
  • Analyst Decision
  • GBIO Strong Buy
  • VATE
  • Analyst Count
  • GBIO 2
  • VATE 0
  • Target Price
  • GBIO $6.50
  • VATE N/A
  • AVG Volume (30 Days)
  • GBIO 649.2K
  • VATE 1.8M
  • Earning Date
  • GBIO 03-05-2025
  • VATE 03-03-2025
  • Dividend Yield
  • GBIO N/A
  • VATE N/A
  • EPS Growth
  • GBIO N/A
  • VATE N/A
  • EPS
  • GBIO N/A
  • VATE N/A
  • Revenue
  • GBIO $18,582,000.00
  • VATE $1,231,500,000.00
  • Revenue This Year
  • GBIO $212.74
  • VATE N/A
  • Revenue Next Year
  • GBIO N/A
  • VATE N/A
  • P/E Ratio
  • GBIO N/A
  • VATE N/A
  • Revenue Growth
  • GBIO 514.08
  • VATE N/A
  • 52 Week Low
  • GBIO $0.72
  • VATE $3.25
  • 52 Week High
  • GBIO $4.65
  • VATE $12.48
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 29.26
  • VATE 78.58
  • Support Level
  • GBIO $0.72
  • VATE $10.92
  • Resistance Level
  • GBIO $1.00
  • VATE $11.85
  • Average True Range (ATR)
  • GBIO 0.07
  • VATE 1.20
  • MACD
  • GBIO -0.00
  • VATE 0.35
  • Stochastic Oscillator
  • GBIO 18.68
  • VATE 91.92

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting stations across the United States.

Share on Social Networks: